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Abstract
Background: The envelope glycoprotein of lymphocytic choriomeningitis virus (LCMV) can efficiently pseudotype
lentiviral vectors. Some strains of LCMV exploit high affinity interactions with a-dystroglycan (a-DG) to bind to cell
surfaces and subsequently fuse in low pH endosomes. LCMV strains with low a-DG affinity utilize an unknown
receptor and display unique tissue tropisms. We pseudotyped non-primate feline immunodeficiency virus (FIV)
vectors using LCMV derived glycoproteins with high or low affinity to a-DG and evaluated their properties in vitro
and in vivo.
Methods: We pseudotyped FIV with the LCMV WE54 strain envelope glycoprotein and also engineered a point
mutation in the WE54 envelope glycoprotein (L260F) to diminish a-DG affinity and direct binding to alternate
receptors. We hypothesized that this change would alter in vivo tissue tropism and enhance gene transfer to
neonatal animals.
Results: In mice, hepatic a- and b-DG expression was greatest at the late gestational and neonatal time points.
When displayed on the surface of the FIV lentivirus the WE54 L260F mutant glycoprotein bound weakly to
immobilized a-DG. Additionally, LCMV WE54 pseudotyped FIV vector transduction was neutralized by pre-
incubation with soluble a-DG, while the mutant glycoprotein pseudotyped vector was not. In vivo gene transfer in
adult mice with either envelope yielded low transduction efficiencies in hepatocytes following intravenous delivery.
In marked contrast, neonatal gene transfer with the LCMV envelopes, and notably with the FIV-L260F vector,
conferred abundant liver and lower level cardiomyocyte transduction as detected by luciferase assays,
bioluminescent imaging, and b-galactosidase staining.
Conclusions: These results suggest that a developmentally regulated receptor for LCMV is expressed abundantly in
neonatal mice. LCMV pseudotyped vectors may have applications for neonatal gene transfer.
Abbreviations: Armstrong 53b (Arm53b); baculovirus Autographa californica GP64 (GP64); charge-coupled device
(CCD); dystroglycan (DG); feline immunodeficiency virus (FIV); glycoprotein precursor (GP-C); firefly luciferase (Luc);
lymphocytic choriomeningitis virus (LCMV); nuclear targeted b-galactosidase (ntLacZ); optical density (OD); PBS/
0.1% (w/v) Tween-20 (PBST); relative light units (RLU); Rous sarcoma virus (RSV); transducing units per milliliter (TU/
ml); vesicular stomatitis virus (VSV-G); wheat germ agglutinin (WGA); 50% reduction in binding (C50).
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Background
Arenaviruses are a family of single-stranded, enveloped,
bisegmented RNA viruses that include the Old World
arenaviruses lymphocytic choriomeningitis virus
(LCMV) and Lassa fever virus, and the New World are-
naviruses Machupo, Junin, and Guanarito. LCMV glyco-
proteins can pseudotype retroviral and HIV-based
lentiviral vectors facilitating studies of virus biology and
gene transfer [1-3]. Encoded by the small RNA frag-
ment, the arenavirus glycoprotein precursor (GP-C) is
post-translationally cleaved to yield GP1 and GP2. GP1
is believed to be responsible for receptor binding fol-
lowed by a pH-dependent fusion step mediated by GP2
[4,5]. Several Old World arenaviruses utilize a-dystro-
glycan (a-DG) as a viral receptor [6]. LCMV is the pro-
totypic Old World arenavirus, with different strains
displaying either high or low affinity for a-DG. Alpha-
DG expression is developmentally regulated, displaying
the highest expression levels in developing tissues
involved in basement membrane assembly [7]. Expres-
sion rises during embryonic stages, peaks in the new-
born, and diminishes in adult tissues [8,9]. Here we
develop and investigate the use of LCMV envelope gly-
coproteins with high or low a-DG affinity for lentiviral
gene transfer applications.
a-DG is a ubiquitously expressed, versatile, evolutio-
narily conserved cell surface receptor that links the
extracellular matrix with the cytoskeleton, making it an
ideal target for pathogen binding [7,10]. The dystrogly-
can complex is transcribed as a precursor peptide that
undergoes post-translational cleavage to produce a- and
b-DG. Noncovalently linked, a- and b-DG act as periph-
eral and transmembrane proteins, respectively. Interest-
ingly, a-DG usage correlates with persistent infection,
disease kinetics, and tropism [11]. The immunosuppres-
sive LCMV isolates WE54, LCMV Cl13, and Traub effi-
ciently target antigen presenting cells (dendritic cells) in
the spleen and perturb their ability to present antigen to
T cells and B cells, resulting in a generalized immuno-
suppression of the host allowing viral persistence. These
three LCMV strains bind to a-DG with high affinity,
unlike non-immunosuppressive LCMV variants
Armstrong 53b, CD4-1, CD8-4 and WE2.2, which
demonstrate low affinity. LCMV Arm53b and WE2.2
replicate primarily in the splenic red pulp and infection is
rapidly resolved. The tropism differences between LCMV
strains, as well as significant infection of DG-/- ES
cells by non-immunosuppressive LCMV variants [12]
suggest that an alternate and currently unidentified viral
receptor is utilized by LCMV strains with low affinity for
a-DG [13].
LCMV Arm53b and clone13 are nearly genetically
identical with the exception of two amino acid
changes, one occurring in the viral polymerase
encoded by the large RNA fragment and the other at
position 260 of GP1 [14]. LCMV WE54 and WE2.2 are
also genetically similar with only one amino acid dif-
ference at position 153 of GP1. Genetic and phenoty-
pic comparison of the New World arenavirus and
LCMV variants led to the observation that amino acid
260 of GP1 plays an important role in their ability to
utilize a-DG [12,15]. Spiropoulou et al. generalized
that a leucine or isoleucine residue at position 260 was
required for high a-DG affinity, while bulky aromatic
residues such as phenylalanine or tyrosine generally
resulted in low affinity [16]. A similar change in
affinity was observed between WE54 and WE2.2, the
result of a serine to phenylalanine mutation at position
153 of GP1. Proper glycosylation, specifically O-
mannosylation [17], and modifications of LARGE
glycosyltransferase [18] also play important roles in
receptor recognition by LCMV. However, LCMV iso-
lates can transduce a-DG-/- mouse ES cells with
reduced efficacy, indicating that a-DG dependence is
not absolute [3,11,19]. Utilization of an alternate
receptor cannot be ruled out as a possibility.
Among the factors potentially limiting the utility of
pseudotyped vectors are low vector titers, envelope
instability following ultracentrifugation, glycoprotein
cytotoxicity, and limited tropism. Able to withstand
ultracentrifugation, LCMV glycoproteins yield MLV and
HIV vector titers similar to the widely used amphotropic
and VSV-G envelopes [1-3]. Stable cell lines constitu-
tively expressing the WE54 envelope have been gener-
ated, demonstrating that the LCMV envelope exhibits
little cytotoxicity in comparison to the VSV-G envelope
[1]. Cannon and colleagues previously demonstrated
successful pseudotyping of MLV-based retroviral vectors
with the Armstrong 53b (Arm53b) envelope glycopro-
tein, and generated the F260L mutation in the Arm53b
GP1 to generate a clone 13-like envelope with high
a-DG affinity [3]. They successfully used these and
other pseudotypes to investigate receptor use and a-DG
affinity among several Old and New World arenavirus
envelopes in vitro [3]. In this report we show that
LCMV envelopes efficiently pseudotype a non-primate
FIV lentiviral vector and maintain the entry properties
seen in wild-type arenaviruses. Furthermore, we modi-
fied the WE54 LCMV envelope with the GP1 mutation
L260F and altered vector a-DG affinity. Here we investi-
gate the expression of a- and b-DG in the liver at
pre- and postnatal time points and document the
in vivo tissue tropisms of these LCMV pseudotypes in
neonatal and adult mice. We hypothesized that a FIV
vector pseudotyped with a LCMV envelope glycoprotein
with low a-DG binding affinity would yield unique
in vivo tissue tropism and enhance gene transfer effi-
ciency in neonatal animals.
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Methods
Glycoprotein enrichment and immunoblotting
Cell surface glycoproteins were isolated for quantifica-
tion of dystroglycan expression as previously described
[20]. Day 18 embryos or postnatal mice were collected
from timed pregnant BALB/c mice, and the livers
pooled from the entire litter. Pooled livers (~200 mg tis-
sue per sample) were homogenized in Tris buffered sal-
ine, pH 7.5 +1.0% TX-100 containing a cocktail of
protease inhibitors and the protein was quantified by
DC assay (BioRad). The resulting homogenate was cen-
trifuged at 4000 g for 15 minutes. A 50% suspension of
wheat germ agglutinin (WGA) agarose beads were then
added (100 μl of packed beads per 100 mg of tissue)
and incubated at 4°C with end over end rotation. The
beads were washed 3X with 10 volumes of Tris buffered
saline, pH 7.5 + 0.1% TX-100. The beads were eluted by
boiling for 5 minutes in 1X Laemlli SDS sample buffer.
Protein samples were separated on 3-15% SDS-PAGE,
transferred to PVDF membranes, and blotted with the
monoclonal antibody IIH6 recognizing the glycosylated
form of a-DG (Upstate), or a polyclonal antibody
against b-DG (Santa Cruz). Western blots were devel-
oped with peroxidase conjugated secondary antibodies,
ECL detection (Pierce) and imaged on a Fluorchem ima-
ging station (Alpha Innotech).
LCMV envelope mutagenesis
Quikchange site-directed mutagenesis (Stratagene,
200518) was used to create a point mutation in the
LCMV WE54 glycoprotein plasmid (Genbank Accession
AJ318512), a kind gift of W. R. Beyer described pre-
viously [1,21]. PAGE-purified primers (LCMV-L260F+,
5’ GGAAAAGACAAAGTTTTTCACTAGGAGACTTG-
CAGGC 3’, and LCMV-L260F-, 5’ GCCTGCAAG
TCTCCTAGTGAAAAACTTTGTCTTTTCC 3’) were
used in the PCR-based mutagenesis to generate a
leucine to phenylalanine mutation at residue 260 of
LCMV GP1, thus creating the envelope construct
LCMV L260F. The L260F mutation was confirmed by
sequencing.
Vector production
The second-generation FIV vector used in this study
was reported previously [22,23]. FIV vectors expressed
the firefly luciferase (Luc) cDNA under the control of a
Rous sarcoma virus (RSV) promoter or nuclear targeted
b-galactosidase (ntLacZ) directed by the CMV promoter.
Envelopes utilized in this study include the glycoproteins
from Indiana strain vesicular stomatitis virus (VSV-G),
baculovirus Autographa californica GP64 (GP64) [24],
LCMV WE54 (also referred to as LCMV-GP(WE-HPI))
[21], and LCMV L260F. Pseudotyped FIV vector parti-
cles were generated by transient transfection of plasmid
DNA as described previously [22]. Pseudotyped viruses
expressing b-gal were visually titered on HT1080 cells
(ATCC, CCL-121) following limiting dilutions of 250-
fold centrifuge concentrated supernatants. Luciferase
expressing vectors were titered by quantitative PCR
following limiting dilution on HT1080 cells and by RT
activity as described [25,26]. Lentiviral vectors for
in vivo experiments were resuspended in 4% (w/v)
a-lactose buffer [23].
Inhibition of endosomal acidification
A549 cells (ATCC, CCL-185) were pretreated with the
carboxylic ionophore monensin (8 μM) (Sigma, M5273)
[27,28] or the weak base ammonium chloride (10 mM).
Pretreatments were applied 1 hour prior to vector trans-
duction at 4°C. The media were changed and FIV vec-
tors pseudotyped with LCMV WE54, VSV-G, or MuLV
amphotropic envelopes were applied at an MOI of 10.
Viruses were incubated on the cells for 30 minutes at
37°C, then fresh media was replaced. Control cultures
received vehicle treatment only. Four days later, gene
transfer efficiency was assessed using Galacto-Light Plus
beta-Galactosidase Reporter Gene Assay System
(Applied Biosystems, BL300P) and normalized for total
protein by Lowry assay.
Binding of FIV pseudotypes to a-DG
a-DG was isolated from skeletal muscle [29], diluted to
a concentration of 10 μg/ml in PBS and immobilized in
96-well EIA/RIA high-bond microtiter plates (Sigma-
Aldrich, CLS3366). Following a 2-hour immobilization
at 25°C, wells were washed 3 times with PBS. Non-spe-
cific binding was blocked by adding 200 μl/well 1%
(w/v) BSA/PBS and incubating for 1 hour at 25°C. Wild-
type LCMV isolates WE54 and WE2.2 were produced in
BHK21 cells (ATCC, CCL-10), precipitated with PEG,
purified on a renografin gradient by ultracentrifugation,
and resuspended in 1% BSA/PBS yielding 107 pfu/ml.
FIV pseudotyped with LCMV WE54 and L260F was pre-
pared and concentrated as stated previously [23], then
diluted to 107 transducing units per milliliter (TU/ml).
Viruses were incubated on immobilized a-DG for 12
hours at 6°C on an orbital shaker (60 rpm) followed by 3
washes with PBS/0.1% (w/v) Tween-20 (PBST).
Detection of bound virus using an ABC detection system
The primary antibody for detection of bound LCMV
was mAb 83.6 anti-GP2 [5], purified IgG, 20 μg/ml in
1% BSA/PBS. Primary antibody was incubated for 2
hours at 6°C followed by 3 washes of PBST. Biotinylated
goat anti-mouse IgG (1:500) secondary antibody in 1%
(w/v) BSA/PBS was added for 1 hour at 25°C. Wells
were washed 3 times with PBST. Steptavidin coupled to
peroxidase (1:500) was added for 1 hour at 25°C
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followed by 3 washes with PBST. Detection using ABTS
[2,2’-azinobis (3-ethylbenzthiazolinesulfonic acid)] sub-
strate allowed for optical density at 405 nm (OD405) to
be recorded in an ELISA reader.
Blocking of transduction of LCMV and FIV pseudotypes
with soluble a-DG
200 PFU of wild-type LCMV or 200 TU of FIV-LCMV
b-gal pseudotypes were diluted in OPTIMEM, 2% (v/v)
FBS with the indicated amounts of purified a-DG or
BSA for 1 hour on ice. The inoculum was added to 90%
confluent cultures of HEK293H cells (ATCC, CRL-
1573) in 8-well LabTeks plates (Nunc) and incubated
for 45 minutes at 37°C/5% CO2. Cells were washed
twice with medium and placed back at 37°C/5% CO2.
24 hours later, cells were fixed with 2% formaldehyde/
0.1% glutaraldehyde in PBS for 15 minutes at 37°C fol-
lowed by a 15 minute blocking with PBS/1% (v/v) FCS
at 25°C. Cells were permeablized with PBS/1% (v/v)
FCS/0.1% (w/v) saponin for 15 minutes at 25°C. LCMV
infection was detected using mAb 113 anti-LCMVNP
[30] (1:200) in PBS/1% (v/v) FCS/0.1% (w/v) saponin for
1 hour at 25°C. Following 2 washes, goat anti-mouse
IgG FITC conjugated secondary antibody was applied
for 45 minutes at 25°C. Fluorescence microscopy using
a 5X objective was used to count NP+ cells. LCMV
b-gal pseudotypes were detected using a b-gal staining
kit (Invitrogen, K1465-01).
In vivo vector administration
Adult BALB/c mice received the following doses of vec-
tor via tail vein: FIV-L260F, 4 × 107 TU; FIV-WE54, 8 ×
107 TU; FIV-GP64, 4 × 107 TU. Neonatal BALB/c mice
(day 2 of life) were injected with 100 μl of centrifuge
concentrated FIV vector via the facial vein using a
30-gauge needle and a 1 ml syringe over 20 seconds.
Vector was not delivered hydrodynamically. The
delivered dose of vector varied depending on the titer of
the concentrated virus. For bioluminescence studies,
FIV-WE54-Luc vector titers allowed for the highest
delivered doses of ~5.1 × 107 TU, followed by FIV-
L260F (1.2 × 107 TU), and FIV-GP64 (1.0 × 107 TU).
For tissue staining studies, the approximate transducing
units delivered were 5.0 × 106 for FIV-WE54-ntLacZ,
4.0 × 106 for FIV-L260F-ntLacZ, and 2.0 × 107 for FIV-
GP64-ntLacZ. The vectors administered in vivo are pre-
sented in Table 1. The University of Iowa Institutional
Animal Care and Use Committee approved this study.
Bioluminescence imaging
Following FIV-Luc delivery, in vivo luciferase expression
was visualized using bioluminescence imaging as
described [24]. At the time points indicated, D-luciferin
(100 μl/10 g of body weight (15 mg/ml in PBS) (Xeno-
gen)) was delivered intraperitoneally to animals using a
26-gauge needle, then mice were placed under 2-3% iso-
flurane anesthesia. Five minutes after D-luciferin injec-
tion, animals were placed in the Xenogen IVIS-200
imaging cabinet (Alameda, CA) and imaged using a
Xenogen IVIS charge-coupled device (CCD) camera
while anesthetized. Imaging data were analyzed and sig-
nal intensity quantified using Xenogen Living Image
software.
Luciferase assays
Three weeks post transduction, animals were euthanized
and the heart, lung, liver, spleen, and kidneys harvested
following vascular perfusion with PBS. Tissues were
homogenized in Tropix lysis buffer (Applied Biosystems)
then centrifuged for 10 minutes at 18,000 × g. Lucifer-
ase assays were performed following manufacturer’s
instructions (Promega, E1501) and quantified using a
PharMingen Monolight 3010 luminometer. Samples
were normalized for protein content by Lowry assay.
Tissue sectioning and X-gal staining
Tissues harvested from animals 3 weeks post-injection
were embedded in Tissue-Tek O.C.T. compound and
frozen at -80°C. 8 μm sections were made using a
Microm Cryostat I (HM 505E). Slides were fixed for 10
minutes at 25°C in 0.5% (v/v) glutaraldehyde/PBS then
washed twice in 1 mM MgCl2/PBS for 10 minutes.
Slides were X-gal stained in Coplin jars for 10 minutes
at 37°C then washed immediately in 1 mM MgCl2/PBS.
Postfixation occurred in 0.5% (v/v) glutaraldehyde, 10%
(v/v) formalin/PBS for 10 minutes at 25°C. Slides were
counterstained 1 minute with nuclear fast red then cov-
erslipped. Quantification of b-gal expression was per-
formed utilizing ImagePro Plus 5.1 (Media Cybernetics)
examining 20X and 40X magnification images as pre-
viously reported [24]. Three images per slide were
Table 1 Vector Doses Administered In Vivo*
Adult mice (luciferase vectors)++
FIV-GP64, 4 × 107 TU
FIV-WE54, 8 × 107 TU
FIV-L260F, 4 × 107 TU
Neonatal mice++
Luciferase Vectors b-Galactosidase Vectors
FIV-GP64, 1.0 × 107 TU FIV-GP64, 2.0 × 107 TU
FIV-WE54, 5.1 × 107 TU FIV-WE54, 5.0 × 106 TU
FIV-L260F, 1.2 × 107 TU FIV-L260F, 4.0 × 106 TU
*Presented as total number of transducing units (TU) delivered to each
animal.
++Vectors administered to adult mice via tail vein. Vectors delivered to
neonatal mice on day 2 of life via the facial vein (100 μl of centrifuge
concentrated vector). The most concentrated preparations were used for each
vector.
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quantified and results averaged from at least 3 slides per
tissue. Manual counting of 40X magnification images
confirmed the accuracy of automated measurements of
transduction efficiency. Cell types were determined by
examining nuclear and cellular morphology.
Results
Developmental expression of a- and b-DG in liver tissue
The availability of target receptors influences the effi-
ciency of gene transfer in neonatal and adult tissues. We
hypothesized that changes in the levels of a-DG or
other viral receptors expressed in newborn versus adult
liver would influence the gene transfer efficiency with
LCMV pseudotyped lentiviral vectors. To test this
hypothesis, we isolated WGA enriched glycoproteins
from neonatal livers and compared the expression of
a- and b-DG by western blotting (Figure 1). The IIH6
antibody for a-DG recognizes the glycosylated form of
a-DG that binds with high affinity to LCMV and lami-
nin. Liver from E18 embryos and early postnatal liver
showed high levels of IIH6 reactive a-DG, while in
adult liver, IIH6 reactive a-DG was barely detected. In
addition, b-DG levels were also high in late embryonic/
neonatal livers compared to adult animals. Interestingly,
although the b-DG levels remained high in P0 and P2
embryos, the level of IIH6 reactive a-DG appeared to
progressively decrease over this time window. This
could either reflect a loss in the a-DG protein or a
decrease in glycosylation efficiency with an overall effect
of loss of functional a-DG on the cell surface.
LCMV glycoproteins efficiently pseudotype feline
immunodeficiency virus
We and others have successfully pseudotyped feline
immunodeficiency virus (FIV)-based lentiviral vectors
with envelope glycoproteins from the baculovirus [24],
rhabdovirus [23,31], coronavirus [32], alphavirus [31],
and filovirus [33] families. Oncoretroviral and HIV-
based lentiviral gene transfer vectors pseudotyped with
the LCMV envelope yield titers similar to VSV-G while
displaying broad tissue tropism [1]. Utilizing a recombi-
nant LCMV envelope (LCMV WE-HPI) that allows for
efficient processing and cell surface expression [21], we
achieved concentrated FIV titers of ≥108 TU/ml.
Entry of LCMV pseudotyped FIV depends on fusion in a
low pH endosomal compartment
Borrow el al. [27] previously demonstrated the pH
dependence of the LCMV entry process. Used as a con-
trol in their experiments, VSV is known to fuse with
cells in a low pH endosome. We sought to demonstrate
that FIV pseudotyped viruses retain their wild-type
entry characteristics. As shown in Figure 2A, pretreat-
ment of A549 cells with either the ionophore monensin,
which prevents endosomal acidification, or the weak
base ammonium chloride inhibited transduction with
FIV vectors pseudotyped with LCMV WE54 and
Figure 1 Developmental expression of dystroglycan proteins in
mouse liver. WGA enriched glycoproteins from livers taken from
pooled E18 embryos, postnatal day zero mice (P0), postnatal day 2
mice (P2), and adult mothers were separated on SDS PAGE.
Immunoblots were performed with IIH6 antibody recognizing the
glycosylated form of a-DG or a polyclonal antibody for b-DG.
Ponceau S stained portions of the blot are shown as a protein
loading control.
Figure 2 LCMV pseudotyped FIV requires low pH endosomes
for efficient transduction. A549 cells were pretreated with 8 μm
monensin or 10 mM NH4Cl to prevent endosomal acidification
followed by application of FIV vectors pseudotyped with LCMV
WE54, VSV-G, or amphotropic envelope. Transduction efficiencies
were measured by b-gal assay and normalized to cells that received
no pretreatment. * indicates P value ≤ 0.05 compared against
untreated control (n = 9). Standard errors are denoted.
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VSV-G. Monensin pretreatment (8 μM) resulted in a
93% decrease in transduction by both LCMV and
VSV-G pseudotyped vectors when compared to trans-
duced cells that received no pretreatment. Similarly,
ammonium chloride pretreatment caused a 77%
decrease in transduction of FIV-LCMV-WE54 and a
93% transduction decrease of FIV-VSV-G. Negative
control amphotropic MLV envelope pseudotyped FIV
displayed no transduction inhibition by monensin or
ammonium chloride. Fusion of the amphotropic envel-
ope occurs at the cell surface and displays pH indepen-
dence [34]. From these findings, we conclude that the
LCMV-WE54 envelope glycoproteins maintain their
native entry and fusion properties when displayed on
the FIV lentivirus, effectively changing the route of
entry that FIV normally takes [35]. These data agree
with previous findings by Sinn et al. demonstrating that
some envelope glycoproteins retain native entry
mechanisms following lentiviral pseudotyping [24].
A single point mutation to LCMV GP1 alters
its a-DG affinity
To investigate the tropism of LCMV WE54 pseudo-
typed vectors with the knowledge that high and low
a-DG affinity arenaviruses display unique tropisms, we
set out to generate a pseudotyped vector possessing
low affinity for a-DG. To alter the a-DG affinity of
LCMV WE54 we mutated residues previously identi-
fied as responsible for a-DG binding (Figure 3A). The
serine residue at position 153 of GP1 was changed to
phenylalanine, which mimics the WE2.2 strain muta-
tion, or the leucine at position 260 was mutated to a
phenylalanine, imitating the Arm53b to Cl13 mutation.
LCMV pseudotyped with WE54 S153F yielded low
titers (≤103 TU/ml), whereas the L260F mutation
(Figure 3A) resulted in a modest loss of titer, approxi-
mately a half log (~8 × 107 TU/ml, n = 6) compared
to parental FIV-WE54 (1 × 108 - 4 × 108 TU/ml, n = 6).
Pseudotyping FIV with the LCMV WE54 double mutant
Figure 3 The LCMV L260F mutation significantly reduces its affinity for a-DG. (A) GP1 of LCMV WE54 was mutated at amino acid position
260 to produce a low affinity a-DG binding envelope (LCMV L260F) similar to the wild-type envelope of LCMV Arm53b. Leucine at position 260
results in high affinity binding to a-DG; phenylalanine reduces its affinity. (B) LCMV pseudotypes and wild type virus were compared for their
affinity to immobilized a-DG in an ELISA-based assay detecting bound virions. (C) Increasing amounts of soluble a-DG were preincubated with
FIV-WE54 (filled squares) or FIV-L260F (filled circles) to neutralize transduction measured by counting positive cells per well. BSA preincubation
was used as a control (open symbols). Wild-type LCMVs with known high (WE54) or low (WE2.2) affinity for a-DG were used as controls for
contrast with pseudovirions and depicted in (B, right panel) and (D). n = 3. Standard deviations are plotted.
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containing the S153F and L260F mutations also resulted
in substantial loss of vector titer and was unsuitable for
study.
To verify altered affinity for a-DG, we performed a
series of competition assays. The virus binding affinity
was determined by immobilizing a-DG in 96-well
microtiter plates followed by incubation with either
WE54 or L260F pseudotyped FIV. Wild-type LCMV
WE54 and WE2.2 viruses were used as controls. At
equivalent viral loads, FIV-WE54 bound to a-DG ~13
times more effectively than FIV-L260F suggesting that
the point mutation altered its a-DG affinity (Figure 3B).
As expected, wild-type WE54 demonstrated strong affi-
nity while WE2.2 displayed little to no affinity (Figure
3B). FIV-WE54 binding, measured by optical density
(OD), was approximately one-third the OD of its wild-
type counterpart.
To further demonstrate that the LCMV WE54 and
L260F envelopes differ in their a-DG affinity, we used
neutralization assays to ask whether soluble a-DG inhib-
ited transduction by preventing receptor binding. With
increasing concentrations of soluble a-DG, vector neu-
tralization was seen with LCMV WE54 pseudotyped FIV
(Figure 3C) and wild-type LCMV WE54 (Figure 3D). No
neutralization was observed from FIV-L260F or wild-type
LCMV WE2.2 as expected. Incubating virus with increas-
ing concentrations of BSA did not change transduction
of any vector. The concentration of soluble a-DG
required to produce a 50% reduction in binding (C50) for
FIV-WE54 was ~20 nM whereas wild-type LCMV WE54
C50 was ~2-3 nM. From these findings, we conclude that
the GP1 L260F mutation of the LCMV WE54 strain
envelope significantly decreases a-DG affinity in the con-
text of a FIV lentiviral pseudotype.
In vivo delivery of LCMV pseudotyped lentiviral vectors
To determine the in vivo tropism of LCMV pseudotyped
FIV, vector was delivered to 6-8 week old adult mice
either locally to the respiratory epithelia [24] or systemi-
cally via tail vein [31]. Attempts to transduce the
respiratory tract in adult mice with FIV-WE54 and FIV-
L260F yielded undetectable luciferase signals in enzyme
assays and bioluminescence imaging following intranasal
or intratracheal delivery (data not shown). Intravenous
vector delivery to adult mice also yielded undetectable
levels of luciferase expression (Figure 4). In contrast,
FIV pseudotyped with the baculovirus GP64 envelope
successfully transduced adult murine tissues following
each delivery route (Figure 4 and data not shown), as
shown previously [26]. The lack of transduction in adult
murine tissues may be due to the developmental regula-
tion of a-DG (the receptor for the WE54 strain of
LCMV), a consequence of post-translational modifica-
tions of a-DG, or related to other post receptor binding
steps [36]. Since a-DG expression is reported to be
most abundant in fetal and neonatal tissues [7-9] and
Figure 1, we next tested LCMV tropism in neonatal
mice.
We delivered FIV lentiviruses pseudotyped with the
LCMV WE54, LCMV L260F, or GP64 envelopes sys-
temically via the facial vein to neonatal BALB/c mice.
Vectors expressed a firefly luciferase reporter directed
by the RSV promoter and expression was assessed 1 and
3 weeks post-injection. FIV pseudotyped with the WE54
envelope (high affinity for a-DG) transduced tissues less
efficiently than FIV-GP64 at 1 week (Figure 5A). Photon
emission appeared to be predominantly localized to the
liver with occasional weak signal evident near the injec-
tion site. In contrast to FIV-WE54, animals transduced
Figure 4 LCMV pseudotyped FIV fails to transduce adult mice
tissues following tail vein injection. 6-8 week old mice were
injected with FIV pseudotypes (LCMV L260F, LCMV WE54, or GP64
left to right) and subsequently imaged to detect bioluminescence
1 and 3 weeks post-injection. Bioluminescence intensities were
measured and means plotted with standard error. n = 6 animals/
group.
Dylla et al. Genetic Vaccines and Therapy 2011, 9:8
http://www.gvt-journal.com/content/9/1/8
Page 7 of 13
with the FIV-L260F vector displayed significantly better
expression (Figure 5A). Interestingly, waiting an addi-
tional 10 minutes after luciferin administration
enhanced signal over the heart for both FIV-GP64 and
FIV-L260F (arrows, Figure 5A, arrows). Similar observa-
tions were made 3 weeks post injection (data not
shown). At the 3 week time point, following CCD ima-
ging, the heart, lung, liver, spleen, and kidneys were har-
vested. Luciferase assays were performed to assess tissue
tropism and expression. Transgene expression was high-
est in the livers of all animals and no expression was
detected in the spleen, lungs, or kidneys. Luciferase
assays revealed that FIV-L260F yielded ~10-fold higher
expression (RLU/μg) in the liver compared to FIV-
WE54 (Figure 5B). FIV-L260F displayed ~5-6 times
higher expression in the liver compared to the heart.
LCMV WE54 displayed no heart transduction. The posi-
tive control GP64 pseudotyped FIV displayed expression
from both the liver and heart.
Neonatal mice next received FIV vectors expressing
nuclear targeted b-gal to examine the tissue and cellular
distribution, as well as to estimate the transduction effi-
ciency. Three weeks post-injection, animals were sacri-
ficed and tissues fixed, cryosectioned, and X-gal stained.
Heart tissue from FIV-GP64 (Figures 6A, B) and FIV-
L260F (Figures 6C, D) treated animals displayed b-gal
Figure 5 Neonatal delivery of FIV-L260F transduces the liver
and heart. One week after facial vein injection of pseudovirions,
mice were imaged utilizing a CCD camera. (A) Representative
photos of mice 1 week postinjection are depicted following
injection with FIV-GP64, FIV-WE54, and FIV-L260F. Waiting an
additional 10 minutes after IP delivery of D-luciferin allowed for
luciferase expression to be detected from the hearts (arrows) in
animals transduced with FIV-GP64 and FIV-L260F, while the hearts of
FIV-WE54 transduced animals displayed no detectable signal. (B)
Three weeks postinjection, the heart, lungs, liver, spleen, and
kidneys were harvested and luciferase assays conducted. Expression
was detected exclusively from liver tissue (black bars) for all
pseudoviruses tested and from hearts (gray bars) for the GP64 and
L260F pseudoviruses. Standard errors are plotted and * denotes
statistical significance (P ≤ 0.05) compared to FIV-WE54 livers. n = 5
for FIV-GP64 and FIV-WE54, 8 for FIV-L260F.
Figure 6 Localization of neonatal transduction in murine
tissues. FIV vectors expressing the LacZ gene were injected into
neonatal mice. Three weeks post-injection, organs were removed
and cryosectioned (8 μm). 4X and 20X magnification images are
shown for FIV-GP64 transduced hearts (A-B) and livers (G-H)
following X-gal staining. Similar images are displayed for FIV-L260F
transduced hearts (C-D) and livers (I-J) and FIV-WE54 transduced
hearts (E-F) and livers (K-L). Spleen and kidneys of vector-transduced
animals were negative. Slides were counterstained with nuclear fast
red. Scale bar in A is 500 μm; B is 200 μm. n = 3.
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positive cells, while little signal was observed with FIV-
WE54 (Figures 6E, F). Additionally, transduced livers
from all animals displayed uniform staining throughout
the tissue (Figures 6G-L). Variability in transduction
efficiency was observed between individual animals
injected with the same vector, likely representing differ-
ences in the effective delivered doses. The FIV-L260F
transduction efficiency ranged from 5-23% positive cells
in liver sections and 1-7% positive cells in the heart.
The cardiac transduction was patchy with predominate
expression observed in cardiomyocytes. By morphologi-
cal criteria, hepatocytes were the predominant target of
liver cell transduction by all envelope glycoproteins
tested (Table 2).
Subsequent cohorts of neonatal animals received the
same three vectors intravenously so that luciferase
expression could be monitored for persistence. Animals
were imaged 1, 3, 6, 9, 12, and 16 weeks post-injection
(Figure 7A). After an initial decline at 1 to 3 weeks,
expression stabilized and remained relatively constant
throughout the duration of the 16 week experiment. As
shown in Figure 7B, starting with an average luciferase
signal intensity of 8.1 × 106 photons/sec/cm2 (+/- 1.8 ×
106 photons/sec/cm2 SE) at the 1 week post-injection
time-point, FIV-L260F expression after 16 weeks aver-
aged 1.0 × 106 photons/sec/cm2 (+/- 2.8 × 105 photons/
sec/cm2 SE). FIV-WE54 expression also persisted and at
the 16 week time-point averaged above 106 photons/sec/
cm2. Expression from control FIV-GP64 was stable at
~107 photons/sec/cm2. Over the 16 week time course,
expression was almost always detected from the liver
area. At early time points it was not uncommon to
detect signal near the site of injection; this signal disap-
peared at later time points.
Discussion
We successfully developed a recombinant LCMV
envelope glycoprotein with altered affinity for its
known receptor, a-DG and used this to pseudotype
FIV. Other strains of LCMV and additional members
of the arenavirus family are a-DG receptor indepen-
dent and typically display unique tropisms. Our modi-
fied WE54 envelope was generated using the
knowledge that in the LCMV Arm53b strain, a leucine
to phenylalanine substitution at position 260 of GP1
alters a-DG affinity. Incorporating this mutation into
the LCMV WE54 glycoprotein did not negatively affect
lentivirus titer and resulted in altered receptor affinity.
The LCMV L260F envelope efficiently transduced neo-
natal murine hepatic and cardiac tissues despite some-
what titer-limited lower delivered doses, and conferred
stable expression.
Differences arose when comparing wild-type LCMV to
lentiviral pseudotypes with respect to their a-DG bind-
ing affinities and neutralization properties. Wild-type
LCMV WE54 bound approximately three times greater
to immobilized a-DG than its pseudotyped counterpart
(Figure 3B). There are multiple possible explanations for
this observation. LCMV envelope glycoproteins normally
form homotetramers on the virion surface. However, the
HIV-1 and SIV lentiviruses have been demonstrated by
electron tomography to possess as few as 8-10 trimers
per virion [37]. Thus, glycoproteins displayed on the
surface of FIV particles may not mirror presentation on
native LCMV virions. This could reduce a-DG binding
and might also decrease recognition by the monoclonal
antibody used against GP2. A difference in the number
of glycoproteins displayed on a virion may also lead to a
disparity between wild-type and pseudotype receptor
binding affinity. Regardless, the results of the viral neu-
tralization and a-DG binding assays confirm that FIV-
WE54 binds significantly better than vector with the
LCMV L260F envelope.
Both LCMV envelopes transduced the neonatal liver
following systemic delivery. Expression from the lenti-
viral vectors persisted at least 4 months (duration of the
experiment). These same pseudotypes poorly transduced
adult liver following tail vein injection while FIV-GP64
transduced the livers of both adult and neonatal mice.
FIV-GP64 transduction, measured by bioluminescence,
was slightly higher than LCMV pseudotypes following
neonatal delivery. In contrast, FIV-WE54 and FIV-
L260F failed to transduce adult mouse tissues following
intravenous, intranasal, or intratracheal delivery. Of
note, the LCMV WE54 pseudotype only transduced
neural stem cells/progenitors following striatal injections
in adult mouse brain, while the L260F pseudotype failed
to transduce cells following striatal injections ([38] and
personal communication from Dr. Beverly Davidson).
The difference in transduction efficiency between neo-
natal and adult animals suggests that arenavirus receptor
expression varies considerably during development.
Indeed our studies of a-DG expression neonatal vs
adult liver tissues revealed a much higher level of
expression of the IIH6 reactive form of alpha-dystrogly-
can perinatally compared to adult animals. We also did
not detect any significant gene transfer by FIV-WE54 in
skeletal muscle even though a-DG is abundantly
expressed in these tissues.
Table 2 Liver transduction with FIV pseudotypes
Transduced cell type, %
Vector % Transduction* Hepatocytes Non-hepatocytes
FIV-GP64-ntLacZ 5.1 (0.6) 99.9 0.1
FIV-L260F-ntLacZ 14.5 (1.2) 99.9 0.1
FIV-WE54-ntLacZ 6.7 (0.8) 99.9 0.1
*Mean (+/- SE).
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Figure 7 LCMV pseudotyped FIV transduction persists in vivo. Luciferase expression was monitored up to 16 weeks following neonatal
injection and signal intensities were quantified using Living Image 2.50 software. 100 μl of FIV-GP64 (an average of 1.0 × 107 TU), FIV-WE54 (~5.1
× 107 TU), or FIV-L260F (~1.2 × 107 TU) were injected via the facial vein 40-60 hours postnatally. Naïve mice received no injection. Images shown
are representative of each condition. Animal groups n = 11 for FIV-GP64, 13 for FIV-WE54, and 17 for FIV-L260F. Standard errors are depicted
with the average signal intensities.
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The glycan(s) present on a-DG that reacts with IIH6
is thought to be critical for LCMV binding and laminin
binding. However, most of the a-DG in the neonatal
liver was of a lower molecular weight (~120 kDa) than
the a-DG glycoform that typically found in adult skele-
tal muscle (156 kDa), but comparable to what is found
in brain dystroglycan (~120 kDa) [20]. The a-DG recep-
tor, which the WE54 envelope binds with high affinity,
exhibits higher expression in late embryonic and neona-
tal stages and declines thereafter [8,9]. Interestingly, the
infection patterns of developing brain by LCMV are also
strikingly dependent on the age of the animal [39].
Therefore, although FIV-L260F shows a lower affinity
for a-DG, the unique glycosylation patterns in neonatal
liver may provide a virus-glycan interaction that favors
low affinity arenavirus binding [18,36]. There may also
be developmentally regulated cell type specific differ-
ences in entry steps that occur after receptor binding,
the tropism of the vector may be strongly affected by
competition of the virus with other ligands that bind
a-DG including laminin and other basement membrane
proteins that are developmentally regulated. More stu-
dies are also needed to identify the potential alternative
receptor for the a-DG low affinity arenaviruses, specifi-
cally of the Old World arenaviruses. This would allow
characterization of the expression patterns of this recep-
tor to determine if its developmental regulation contri-
butes to arenavirus tropism.
Another possible explanation for the differing trans-
duction efficiencies in neonatal and adult mice may
relate to hepatocellular proliferation rates. Park et al.
demonstrated improved lentiviral transduction of hepa-
tocytes in vivo following cell cycle progression [40].
Further support of this hypothesis came from correlat-
ing vector transduction efficiencies and BrDU labeling
in mice of different ages [41]. It is known that the rates
of hepatocyte proliferation are higher in newborn than
adult animals [42,43]. A requirement for cell prolifera-
tion may also help explain the relatively low efficiency
of LCMV pseudotyped vector tropism for adult striated
muscle cells, which have high a-DG expression, but lack
nearly any detectable mitotic activity under normal con-
ditions. However, other physiological differences
between neonatal and adult mice cannot be ruled out.
The FIV-L260F envelope conferred higher transgene
expression than FIV-WE54 in neonatal mice initially (1
and 3 weeks post-injection) and subsequently displayed
similar levels of expression for the remaining 13 weeks
of observation (Figure 7). This is despite an average
delivered vector dose approximately 20% of FIV-WE54.
Additionally, FIV-L260F displayed a unique tropism that
included cardiomyocyte transduction. A general obser-
vation was that heart transduction from FIV-L260F was
primarily located in ventricular free walls, although rare
transduction was also observed in the interventricular
septum. Most expression was found in the outer 300
μm of the myocardium. In contrast, FIV-GP64 displayed
more uniform transduction across the full thickness of
the myocardium. These observations suggest coronary
circulation as the route of delivery to these areas rather
than transduction through the endocardium.
Conclusions
LCMV pseudotyped FIV may have applications for
delivery of genes to hepatocytes [1] and cardiomyo-
cytes during development for experimental or thera-
peutic applications. Neonatal gene transfer has several
posited advantages and has received increased interest
with achievements utilizing oncoretroviral and lenti-
viral vectors [44-51]. Hereditary disorders that cause
specific organ damage prenatally or neonatally could
be treated early before irreversible damage. The neona-
tal immune system is less mature, and may allow
enhanced transduction and facilitate transgene toler-
ance [52,53]. A practical advantage of neonatal gene
transfer is that an increased delivered vector/body
mass can be achieved experimentally, perhaps allowing
for transduction of a larger number of the cells in a
tissue, and increasing the likelihood of progenitor cell
targeting when integrating vectors are used. In sum-
mary, LCMV L260F pseudotyped FIV has a reduced
affinity for a-DG receptor and may have applications
as a neonatal gene transfer vector for cardiac and
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